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Abstract
We have investigated signaling pathways leading to angiotensin II (Ang II) activation of mitogen-activated protein kinase (MAPK) in
hepatocytes. MAPK activation by Ang II was abolished by the Ang II type 1 (AT1) receptor antagonist losartan, but not by the Ang II type 2
(AT2) receptor antagonist PD123319. Ang II (100 nM) induced a rapid phosphorylation of Src (peak approximately 2 min) and focal adhesion
kinase (FAK, peak approximately 5 min) followed by a decrease to basal levels in 30 min. An increased association between FAK and Src in
response to Ang II was detected after 1 min, which declined to basal levels after 30 min. Treatment with the Src kinase inhibitor PP-1 inhibited
FAK phosphorylation. Downregulation of PKC, intracellular Ca2+ chelator BAPTA or inhibitors of PKC, Src kinase, MAPK kinase (MEK),
Ca2+ /calmodulin dependent protein kinase, phosphatidylinositol 3-kinase all blocked Ang II-induced MAPK phosphorylation. In contrast to
other cells, there was no evidence for the role of EGF receptor transactivation in the activation of MAPK by Ang II. However, PDGF receptor
phosphorylation is involved in the Ang II stimulated MAPK activation. Furthermore, Src/FAK and Ca/CaM kinase activation serve as potential
links between the Ang II receptor and MAPK activation. These studies offer insight into the signaling network upstream of MAPK activation
by AT1 receptor in hepatocytes. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Angiotensin II (Ang II), a central component of the
renin–angiotensin system, plays an important role in blood
pressure regulation. Ang II stimulates the adrenal cortex to
release aldosterone and the hypothalamus to secrete vaso-
pressin. Ang II also constricts vascular smooth muscle cells,
leading to increases in blood pressure. In the kidney, Ang II
modulates proximal tubular reabsorption of water and
sodium [1]. In addition to these effects, Ang II is also a
potent growth factor for vascular smooth muscle cells and
cardiomyocytes, implying that Ang II is involved in car-
diovascular diseases such as hypertension and atheroscle-
rosis [2]. In the liver, Ang II increases angiotensinogen
mRNA and angiotensinogen secretion, thus affecting the
renin–angiotensin system [3].
Two major isoforms of Ang II receptors, the Ang II type
1 and type 2 (AT1 and AT2), have been established [4,5].
AT1 receptor activation by Ang II stimulates phospholipase
C through activation of Gq family protein, resulting in the
generation of inositol (1,4,5)-trisphosphate (IP3) and 1,2-
diacylglycerol (DAG) [6] from phosphatidylinositol 4,5-
bisphosphate (PIP2), leading to intracellular calcium release
[7], and activation of protein kinase C [8]. It has been shown
that Ang II can inhibit adenylate cyclase, activate guanylate
cyclase, release prostaglandins, and induce the expression of
transcription factors including c-fos, c-jun, c-myc, and
signal transducers and activators of transcription (STAT)
[9]. Ang II also stimulates mitogen-activated protein kinase
(MAPK) in liver epithelial cells, glomerular mesangial cells
and vascular smooth muscle cells [10,11]. Accumulating
evidence suggests that Ang II evokes tyrosine phosphory-
lation of several signaling molecules, leading to the activa-
tion of MAPK. However, the signaling events that mediate
Ang II-stimulated MAPK in the liver are poorly understood.
MAPKs belong to the family of serine–threonine kinases
that are activated by various stimuli. In mammalian cells,
the MAPK family contains extracellular signal-regulated
kinases 1 and 2 (ERK1/p44mapk and ERK2/p42mapk) as well
as the c-Jun N-terminal kinases (JNK), and p38mapk. They
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integrate multiple signals from various second messengers,
leading to cellular proliferation and differentiation. The
activated MAPK in liver cells translocates to nucleus [12],
where it may regulate the expression of transcription factors.
In response to growth factors, p42mapk and p44mapk are
activated either through receptor tyrosine kinases (RTKs) or
through G-protein-coupled receptors (GPCRs) [13,14].
Activation of the epidermal growth factor receptor (EGF-
R), an RTK, recruits the guanine nucleotide exchange factor,
son-of-sevenless (Sos) through adaptor proteins, Shc and
Grb2, thereby initiating a sequential cascade from p21ras
(Ras), Raf-1 and MAPK kinase (MEK) to MAPK. In
addition, stimulation of various GPCRs such as lysophos-
phatidic acid (LPA) receptor, bradykinin receptor, and Ang
Fig. 1. Ang II-induced phosphorylation of MEK and MAPK is mediated by the AT1 receptor. (A) Hepatocytes were stimulated with Ang II (100 nM) for the
indicated times. After cell lysis, cell lysates were directly immunoblotted with anti-phospho MEK or anti-phospho p42/44 MAPK pAb, respectively. Blots
shown are representative of three separate experiments. Arrows indicate the position of MEK or p42/44 MAPK. (B) Hepatocytes were treated with 10 AM
losartan, an AT1 receptor antagonist, or 10 AM PD 123319, an AT2 receptor antagonist, for 30 min, then stimulated with 100 mM Ang II for 5 min. The cell
lysates were analyzed by immunoblotting with anti-phospho MAPK pAb. Blot shown is representative of four separate experiments. Arrows indicate the
position of p42/44 MAPK. (C) Quantitative results of panel B were determined by laser densitometry and are presented as meanF S.E. (four experiments).
Values are expressed as fold changes over unstimulated control cells. *P < 0.05 vs. control; #P< 0.05 vs. Ang II-treated cells.
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II receptor also rapidly increase MAPK activity [15,16,21].
The mechanisms leading to MAPK activation via Gi-
coupled receptors appear to be mediated by the release of
Ghg complexes from pertussis toxin (PTX)-sensitive G
proteins [15]. In contrast, the MAPK activation through
Gq-coupled receptors is PTX insensitive and PKC depend-
ent [17]. Recently, several lines of evidence indicate that
GPCRs, including the AT1R, transactivate growth factor
receptors, e.g. EGF-R and platelet-derived growth factor
receptor h (hPDGF-R). In human mesangial cells, Ang II
stimulation increased phosphotyrosine content of hPDGF-R
[18]. It also has been shown that MAPK activation by Ang
II was mediated via EGF-R tyrosine phosphorylation in rat
liver epithelial cells [19] and vascular smooth muscle cells
[20]. These data indicate that RTKs may play a role in
GPCRs activation of MAPK. However, it is not known
whether cross-talk between GPCRs and growth factor
receptors has any effect on MAPK activation in hepatocytes.
In the present study, we have investigated upstream signal-
ing pathways leading to Ang II activation of MAPK in rat
primary culture of hepatocytes.
2. Materials and methods
2.1. Materials
Ang II, phorbol-12-myristate-13-acetate (PMA), cholera
toxin (CTX), PTX, protease inhibitors (aprotinin, leupeptin,
and pepstatin A) and PD123319 were obtained from Sigma
Chemical Co. (St. Louis, MO). Losartan potassium was a
gift from Dupont-Merck Pharmaceutical Company (Wil-
mington, DE). Src kinase inhibitors herbimycin A and PP-
1, and the protein kinase C inhibitor Ro 31-8220 and GF
109203X and GP antagonist-2 (Pyr-Gln-D-Trp-Phe-D-Trp-
Met-NH2) were purchased from Biomol Research Labora-
tory (Plymouth, PA). The calcium/calmodulin (Ca2+ /CaM)
protein kinase inhibitors KN-62, KN-93 and KN-92, EGF-R
autophosphorylation inhibitor AG1478, and PDGF-R auto-
phosphorylation inhibitor AG1296 were from Calbiochem-
Novabiochem Corporation (San Diego, CA). The MEK
inhibitor U-0126 was purchased from Promega (Madison,
WI). BAPTA-AM and fura-2/AM were obtained from
Molecular Probes (Eugene, OR). AT1 receptor polyclonal
antibody (pAb), focal adhesion kinase (FAK) pAb, c-Src
monoclonal antibody (mAb), EGFR pAb, agarose-conju-
gated c-Src, and agarose-conjugated EGFR from Santa Cruz
Biotechnology (Santa Cruz, CA). Agarose-conjugated FAK
Ab was from Upstate Biotechnology (Lake Placid, NY).
MEK1/2, phospho-MEK1/2, p44/42 MAPK and phospho-
p44/42 MAPK pAb were from Cell Signaling Inc. (Beverly,
MA). The mouse monoclonal anti-phosphotyrosine anti-
body was purchased from Zymed Laboratory (San Fran-
cisco, CA). Anti-Src [pY418] phosphospecific antibody was
purchased from BIOSOURCE International (Camarillo,
CA). The goat anti-rabbit immunoglobulin G (IgG) horse-
radish peroxidase conjugate and goat anti-mouse IgG horse-
radish peroxidase conjugate were purchased from Bio-Rad
Laboratories (Hercules, CA).
2.2. Isolation of rat hepatocytes and treatment of
hepatocytes
Isolated rat hepatocytes were prepared by collagenase
perfusion protocol as described previously [21]. The hep-
atocytes (3 106 cells/60 mm dish) were plated on to col-
lagen-coated culture dishes in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum. After
2 h, the medium was changed to DMEM containing 0.1%
fetal bovine serum. After 24 h, cell were stimulated with
Ang II for 5 min. Cells were chilled immediately by placing
the dishes onto ice and rinsed twice with ice-cold phosphate
buffered saline (PBS). Next, 0.5 ml of ice-cold lysis buffer
containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM
EGTA, 100 mM NaF, 1.5 mM MgCl2, 10 mM sodium
pyrophosphate, 10% glycerol, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 1 mM sodium orthovanadate, 10 mM h-
glycerophosphate, 10 Ag/ml aprotinin, 10 Ag/ml leupeptin,
and 10 Ag/ml pepstatin A was added. Cells were scraped
into lysis buffer and transferred into test tubes at 4 jC. After
centrifugation at 12,000 g for 10 min at 4 jC, the super-
natant was collected and protein concentration was meas-
ured using the Bio-Rad DC protein assay kit.
Fig. 2. Ang II activates FAK phosphorylation in hepatocytes. Hepatocytes
were stimulated with Ang II (100 nM) for the indicated times. After cell
lysis, immunoprecipitation (IP) was performed with agarose-conjugated
FAK Ab, then immunoblotted with anti-phosphotyrosine antibody (upper
panel), anti-phospho-FAK (Tyr397) antiserum (Upstate Biotechnology)
(middle panel), and anti-FAK pAb (lower panel). Blots shown are re-
presentative of three separate experiments. Arrows indicate the position of
total phospo-FAK, phospho-FAK at Tyr397, and FAK protein.
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2.3. Western blotting
The whole cell lysate (20 Ag) was subjected to 7.5% or
10% SDS-PAGE and electrophoretically transferred onto
nitrocellulose membrane (Bio-Rad) using Bio-Rad Trans-
Blot apparatus. The membrane was washed with 20 mM
Tris, pH 7.5 containing 0.1% Tween-20 and 150 mM NaCl
(TBST) and incubated with TBST containing 5% nonfat dry
milk for 1 h at room temperature. After washing with TBST,
MEK, MAPK, phospho-MEK, and phospho-MAPK were
detected by Western blot analysis with use of a 1:1000
dilution of respective antibodies overnight at 4 jC and a
secondary antibody conjugated horseradish peroxidase for 1
h at room temperature. The horseradish peroxidase was
detected by enhanced chemiluminescence (ECL) (Pierce).
The membrane treated with ECL reagent was exposed to X-
ray film to detect the protein band and those corresponding
to MEK, MAPK, phospho-MEK or phospho-MAPK were
quantified by laser densitometry.
2.4. Immunoprecipitation and immunoblotting
Cell lysate protein (500 Ag) was mixed with the agarose-
conjugated phosphotyrosine, EGF-R, FAK or Src Ab for
immunoprecipitation, rocked at 4 jC overnight and centri-
fuged for 10 min at 12,000 g. Immunoprecipitates were
washed three times with lysis buffer, solubilized in Laemm-
li’s sample buffer with dithiothreitol at 100 jC for 10 min.
Immunoprecipitates were separated with use of SDS-PAGE
and protein phosphorylation or association was detected by
immunoblotting with Src, FAK or anti-phosphotyrosine
antibodies as described above. For repeated immunoblot-
ting, the membrane was stripped in 62.5 mM Tris–HCl, pH
6.7, 2% SDS, and 0.1 M h-mercaptoethanol for 30–45 min
at 50 jC.
2.5. Measurement of [Ca2+]i in single hepatocytes
Hepatocytes were plated onto gelatin-coated coverslips at
a density of 2 105 cells/cm2 and kept in the DMEM
containing 10% FBS for 2 h at 37 jC. The coverslip was
washed once with PBS and the medium was changed to
DMEM containing 0.1% fetal bovine serum. After 24 h, the
cells were loaded with 2 AM fura-2/AM for 2 h at room
temperature in HEPES buffered Hank’s medium, containing
147 mM NaCl, 4 mM KCl, 1.2 mM MgCl2, 1.2 mM
potassium phosphate, 10 mM HEPES (pH 7.4), and 1 mM
CaCl2, with 2% BSA and 200 AM sulfinpyrazone. After
loading, the coverslip was washed once with HEPES
Fig. 3. Ang II activates Src phosphorylation and increases the formation of
a complex between FAK and Src in hepatocytes. (A) Hepatocytes were
stimulated with Ang II (100 nM) for the indicated times. After cell lysis,
immunoprecipitation (IP) was performed with agarose-conjugated Src Ab,
then immunoblotted with anti-phosphotyrosine antibody (upper panel),
anti-Src Ab (middle panel), and anti-FAK pAb (lower panel). Arrows
indicate the position of phospho-Src, total Src, and FAK-Src complex. (B)
Cell lysates were separated by SDS-PAGE and immunoblotted with an anti-
Src [pY418] phosphospecific Src Ab. Blots shown are representative of
three separate experiments.
Fig. 4. The involvement of Ca2+ and Src in Ang II-induced FAK
phosphorylation. Hepatocytes were pretreated with 10 AM BAPTA-AM or
10 AM PP-1 for 30 min and then stimulated with Ang II (100 nM) for 5
min. Cell lysates were immunoprecipitated (IP) with agarose-conjugated
FAK Ab, followed by immunoblotting with anti-phosphotyrosine mAb or
anti-FAK pAb. Blot shown is representative of three separate experiments.
Arrow indicates the position of FAK. (CTL: control, i.e. without agonist or
inhibitor treatment).
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buffered Hank’s medium and the cells were incubated in
HEPES buffer. All experiments were performed at 37 jC.
Fluorescence in individual cells was measured with an
InCyt I/P-2k Fluorescence Imaging and Photometry Sys-
tem (Intracellular Imaging Inc., Cincinnati, OH). The images
were processed through an IBM computer using an InCyt
Im2k Imagine Acquisition and Analysis Software.
2.6. Data analysis
All results are expressed as meanF S.E. and were ob-
tained by combining data from individual experiments. Sta-
tistical analyses were made using the Student’s t-test (two-
tailed, unpaired). Differences with a P-value of < 0.05 were
considered statistically significant.
3. Results
3.1. Ang II-induced phosphorylation of MEK and MAPK is
mediated by the AT1 receptor
We have established earlier that MAPK activation was
dependent on the concentration of Ang II; activation was
detectable at 1 nM and maximal at 100 nM [21]. Hence, we
used 100 nM Ang II in subsequent experiments. We also
evaluated the Ang II response and protein level of the AT1
receptor in the cultured hepatocytes. Ang II (100 nM)
caused MAPK phosphorylation in hepatocytes cultured for
3 h and this response could be found even after 48 h of
hepatocyte culturing. Immunoblotting with AT1 receptor
antibody indicated that protein level of AT1 receptor did
Fig. 5. Effect of CTX and PTX on Ang II-induced MAPK phosphorylation. (A) Hepatocytes were preincubated with 5 Ag/ml CTX and 100 ng/ml PTX for
24 h, then stimulated with Ang II (100 nM) for 5 min. Cell lysates were separated by SDS-PAGE and immunoblotted with an anti-phospho MAPK pAb. Blot
shown is representative of five separate experiments. Arrows indicate the position of p42/44 MAPK. (B) Results in Awere quantified by laser densitometry and
are presented as meanF S.E. (five experiments). Values are expressed as fold changes over unstimulated control cells. *P < 0.05 vs. control. (C) Hepatocytes
were preincubated with GP antagonist-2 (GP-2) for 15 min, then stimulated with Ang II (100 nM) for 5 min. Cell lysates were separated by SDS-PAGE and
immunoblotted with anti-phospho MAPK pAb. Blot shown is representative of three separate experiments.
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not change after 48 h of culturing. These data suggested the
response of Ang II and expression of AT1 receptor in
cultured hepatocytes were still intact. Expression of AT1
receptor in hepatocytes has also been documented by other
investigators [26,27]. Analysis of MEK and MAPK activity
following Ang II stimulation revealed a similar pattern of
activation; MEK and MAPK phosphorylation were detect-
able within 1 min after stimulation, peaked at 5 min, and
returned to basal level at 20 min (Fig. 1A). To verify that the
activation of MAPK by Ang II was receptor dependent and
to determine which Ang II receptor subtype mediates this
stimulation, MAPK phosphorylation was evaluated in the
presence or absence of losartan or PD123319 (10 AM), AT1
or AT2 receptor specific antagonists, respectively. Losartan
completely inhibited this response whereas PD123319 had
no effect (Fig. 1B,C). These results indicated that Ang II-
Fig. 6. The involvement of Ca2+ in Ang II-activated MAPK phosphorylation in hepatocytes. (A) Hepatocytes were incubated with or without 10 AM BAPTA-
AM for 1 h. Cells were washed in the buffer for the measurement of intracellular Ca2+ levels using fura 2-AM and stimulated with Ang II (100 nM). A typical
trace from three separate experiments is shown. (B) Hepatocytes were pretreated with or without BAPTA-AM (10 AM) for 30 min or EGTA (5 mM) for 5 min,
and then stimulated with Ang II (100 nM) for 5 min. Cell lysates were separated by SDS-PAGE and immunoblotted with anti-phospho MAPK pAb. Blot
shown is representative of three separate experiments. Arrows indicate the position of p42/44 MAPK. (C) Laser densitometric data of B. Results are presented
as meanF S.E. (three experiments). Values are expressed as fold changes over unstimulated control cells. #P< 0.05 vs. Ang II-treated cells.
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stimulated MAPK phosphorylation is mediated via AT1
receptor.
3.2. Ang II induces FAK and Src phosphorylation in
hepatocytes
Primary cultures of hepatocytes were stimulated with 100
nM Ang II for various times and lysed. The cell lysates were
used for immunoprecipitation and immunoblotting studies.
As shown in Fig. 2, the total FAK phosphorylation peaked
5 min after stimulation with Ang II; increasing 9.7F 0.9-
folds above control values (n = 3), and returned to near-basal
levels after 30 min (upper panel). Ang II also induced au-
tophosphorylation of FAK at Tyr397 (peak 5 min and
4.4F 0.7-folds above control; n = 3), using a site-specific
Ab that recognizes the phosphorylated Tyr397 (middle pa-
nel). These results suggest that Ang II induced autophos-
phorylation of FAK. Endogenous FAK can also be tyrosine
phosphorylated at additional sites (e.g. Tyr577 or Tyr925).
These changes were not due to change in FAK protein levels
(Fig. 2, lower panel). Ang II also stimulated Src phosphor-
ylation, highest at 2 min followed by rapid decline to basal
level within 30 min (Fig. 3A, upper panel). This result was
further confirmed by using [pY418] Src Ab, which is a phos-
phospecific Src antibody and recognizes the autophospho-
rylation residue of c-Src (Fig. 3B). Src protein levels did not
change during these treatments (Fig. 3A, middle panel; B,
lower panel).
3.3. Ang II induces the formation of a complex between FAK
and Src in hepatocytes
To determine interaction between FAK and Src, hepato-
cytes were treated with Ang II for different time periods and
then lysed in buffer containing 1% Triton X-100 in the
presence or absence of SDS and sodium deoxycholate. The
cell lysates were immunoprecipitated with agarose-conju-
gated Src Ab and immunoblotted with FAK Ab. The immu-
nocomplexes of FAK and Src were not detected by using
lysis buffer containing 1% Triton X-100, although equal
amount of Src protein was detected in these lysates (data not
shown). However, the immunocomplexes of FAK and Src
were detected by using lysis buffer containing Triton X-100,
SDS and sodium deoxycholate. As shown in Fig. 3A (lower
panel), Ang II increased co-immunoprecipitation of FAK
and Src (peak 1 min) (2.6F 0.1-fold increase compared
with control; n = 3), which declined to the basal level after
30 min.
3.4. Role of Ca2+ and Src in FAK phosphorylation induced
by Ang II
To examine whether Ca2+ was required for phosphor-
ylation of FAK in response to Ang II, hepatocytes were
pretreated with BAPTA-AM, an intracellular Ca2+ chelator
prior to stimulation with Ang II. The cell lysates were
immunoprecipitated with agarose-conjugated FAK Ab and
Fig. 7. Involvement of Ca2+ /CaM dependent pathway in Ang II-induced MAPK phosphorylation. Hepatocytes were pretreated with KN-62 (1–10 AM) (A),
KN-93 (1–10 AM) (B), or KN-92 (1–10 AM) (C) for 30 min, then stimulated with Ang II (100 nM) for 5 min. Cell lysates were separated by SDS-PAGE and
immunoblotted with anti-phospho MAPK pAb. Blot shown is representative of three separate experiments. Arrows indicate the position of p42/44 MAPK.
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immunoblotted with anti-phosphotyrosine mAb. As shown
in Fig. 4, BAPTA-AM did not prevent FAK phosphoryla-
tion induced by Ang II, suggesting FAK phosphorylation
induced by Ang II was independent of Ca2+ mobilization.
To investigate the role of Src in the regulation of FAK
phosphorylation, hepatocytes were treated with 10 AM PP-
1, a selective inhibitor of the pp60c-Src tyrosine kinase, and
then stimulated with Ang II. PP-1 markedly inhibited the
FAK phosphorylation in response to Ang II (Fig. 4),
suggesting that Src kinase is involved in the FAK phosphor-
ylation.
3.5. Effects of PTX and CTX on Ang II-induced MAPK
phosphorylation
The AT1 receptor has been reported to be coupled to Gi
or Gq in different cell types [22–25]. To investigate the
involvement of G proteins in the activation of MAPK by
Ang II, we tested the effect of PTX, which inactivates Gi by
ADP-ribosylation of the a subunit, and CTX, which blocks
Gs, on Ang II-induced MAPK phosphorylation in hepato-
cytes. As shown in Fig. 5, treatment of hepatocytes with
CTX (5 Ag/ml) for 24 h did not affect Ang II-induced
MAPK phosphorylation. PTX (100 ng/ml) pretreatment had
no effect on basal MAPK activity but caused a 38F 9%
(F S.E.; n = 3) inhibition of p44 MAPK and 42F 8%
(F S.E.; n= 3) inhibition of p42 MAPK activities stimu-
lated by Ang II. We performed additional experiments to
test the involvement of PTX-sensitive G proteins in Ang II-
stimulated MAPK activation. Hepatocytes were treated with
GP antagonist-2 (1–10 AM), a peptide derived from sub-
stance P that inhibits activation of Gi and Go proteins [28],
for 15 min, and then stimulated with Ang II. As shown in
Fig. 5C, GP-2 at 5 AM decreased Ang II-induced MAPK
phosphorylation by about 75.7F 2.1% (n = 3) for p42
MAPK and 84.1F 2.4% (n = 3) for p44 MAPK without
affecting the basal MAPK phosphorylation. These data
suggest that PTX-sensitive G proteins are involved in the
Ang II-stimulated MAPK phosphorylation. GP antagonist-
2A has been used as inhibitor for Gq [28,29]. However, we
have found that GP antagonist-2A increased the basal level
of MAPK phosphorylation and therefore could not be used
as a tool. Any involvement of Gq therefore cannot be ruled
out.
Fig. 8. Ang II does not increase phosphotyrosine content of EGF receptor. (A) Hepatocytes were stimulated with 100 nM Ang II for indicated times. After cell
lysis, immunoprecipitation (IP) was performed with agarose-conjugated EGF receptor Ab. Precipitates were analyzed by immunoblotting with anti-pTy mAb
and anti-EGF receptor pAb. (B) Hepatocytes were pretreated with AG 1478 (100 nM) or vehicle for 30 min and stimulated with Ang II (100 nM) for 5 min.
After cell lysis, lysates were separated by SDS-PAGE and immunoblotted with anti-phospho MAPK pAb. Blot shown is representative of three separate
experiments. Arrows indicate the position of p42/44 MAPK. (C) Quantitative results were determined by laser densitometry of B and are presented as
meanF S.E. (three experiments). Values are expressed as fold changes over unstimulated control cells. (D) Hepatocytes were pretreated with AG 1478
(100 nM) or vehicle for 30 min and stimulated with EGF (10 ng/ml) for 5 min. Cell lysates were immunoprecipitated with agarose-conjugated EGF receptor Ab
and then probed with anti-pTy mAb or anti-EGF receptor pAb. Blot shown is representative of three separate experiments. (E) Hepatocytes were preincubated
with AG 1296 (5–50 AM) for 16 h, then stimulated with Ang II (100 nM) for 5 min. Cell lysates were separated by SDS-PAGE and immunoblotted with anti-
phospho MAPK pAb. Blot shown is representative of three separate experiments.
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3.6. Involvement of Ca2+/CaM dependent protein kinase
(Ca/CaM kinase) in Ang II-induced MAPK phosphorylation
Exposure of hepatocytes to Ang II markedly increased
intracellular Ca2+ levels from 98.7F 6.9 to 269.3F 15.1
nM, and this increase was completely blocked by pretreat-
ment with the 10 AM BAPTA-AM (Fig. 6A) but not by
extracellular Ca2+ chelator EGTA (data not shown). To
investigate the effect of cytosolic Ca2+ chelation on MAPK
phosphorylation induced by Ang II, hepatocytes were pre-
treated with 10 AM BAPTA-AM for 30 min, prior to
stimulation with Ang II. As shown in Fig. 6B, pretreatment
of hepatocytes with BAPTA-AM decreased Ang II-induced
MAPK phosphorylation by about 43.5F 6.2% (n = 5) for
p42 MAPK and 40.3F 6.7% (n = 5) for p44 MAPK and
EGTA did not affect MAPK phosphorylation by Ang II
(Fig. 6C). Elevation of cytosolic Ca2+ activates a variety of
enzymes through interaction with calmodulin. To examine
whether Ca2+ /CaM kinase mediates MAPK activation by
Ang II, hepatocytes were preincubated with the Ca2+ /CaM
kinase inhibitor KN-62 (1–10 AM) or KN-93 (1–10 AM)
for 30 min, and then stimulated with Ang II. As shown in
Fig. 7A,B, KN-62 and KN-93 had no effect on basal MAPK
activity, but KN-62 at 5 AM decreased Ang II-induced
MAPK phosphorylation by about 46.5F 11.8% (n = 4) for
p42 MAPK and 48.7F 5.2% (n = 4) for p44 MAPK and
KN-93 showed a similar pattern. In order to rule out non-
specific effects of the inhibitor, KN-93, its inactive analog
KN-92 was used. As shown in Fig. 7C, KN-92 had no effect
on either basal or Ang II-induced MAPK activity. Taken
together, these results suggest the dependency of Ang II-
stimulated MAPK on a Ca2+ /CaM kinase.
Fig. 8 (continued ).
Fig. 9. Ang II stimulates MAPK phosphorylation through PKC-dependent
pathway. Hepatocytes were preincubated with Ro 31-8220 (A) or GF
109203X (B) for 30 min, or pretreated with 1 AM PMA (C) for 24 h to
downregulate PKC activity, then stimulated with Ang II (100 nM) or PMA
(100 nM) for 5 min. Cell lysates were separated by SDS-PAGE and
immunoblotted with anti-phospho MAPK pAb. Blot shown is representa-
tive of three separate experiments.
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3.7. Involvement of EGF-R phosphorylation or PDGF-R
phosphorylation in Ang II-stimulated MAPK activation
We have shown earlier [21] that the EGF (10 ng/ml; 1.67
nM) activated MAPK, with approximately eight-fold
increase occurring within 5 min and indicated that the MAPK
activation by EGF is intact in hepatocytes cultured for 24 h.
AG1478 (10  7 M), an inhibitor of intrinsic tyrosine kinase
activity of the EGF-R, blocked EGF receptor autophosphor-
ylation (Fig. 8D). In rat VSMC cultures, Ang II was shown to
induce tyrosine phosphorylation of EGF-R, suggesting that
EGF-R may play an essential role in the GPCR-mediated
MAPK activation pathway [20]. To determine the involve-
ment of the EGF-R and to examine the effect of Ang II on the
Fig. 10. Effects of inhibition of PtdIns-3-kinase, Src kinase and MEK on Ang II-induced MAPK phosphorylation. Hepatocytes were pretreated with (A) PtdIns-
3-kinase inhibitor (LY294002; 10, 50, or 100 AM) for 30 min, or (B) Src tyrosine kinase inhibitor (herbimycin, PP-1, 10 AM) for 1 h, or (C) MEK inhibitor (U-
0126, 10 AM) for 1 h, then stimulated with Ang II (100 nM) for 5 min. Cell lysates were separated by SDS-PAGE and immunoblotted with anti-phospho
MAPK pAb. Blot shown is representative of three separate experiments. Arrows indicate the position of p42/44 MAPK. Laser densitometric data of B are
shown in lower panel. Results are presented as meanF S.E. (three experiments). Values are expressed as fold changes over unstimulated control cells. #P < 0.05
vs. Ang II-treated cells.
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phosphotyrosine content of the EGF-R, samples were immu-
noprecipitated with an anti-EGFR antibody and analyzed by
immunoblotting with an anti-pTymAb. In contrast to the Ang
II effect on VSMC, we could not detect EGF-R phosphor-
ylation in hepatocytes (Fig. 8A). EGF-R protein did not
change as shown by reprobing with anti-EGFR pAb (Fig.
8A). To establish further that EGF-R phosphorylation is not
involved in Ang II-stimulated MAPK, hepatocytes were
pretreated for 30 min with AG1478 (10 7 M), stimulated
with Ang II for 5 min, and then subjected to immunoblot
analysis with anti-phosphoMAPK pAb. AG1478 (an EGF-R
autophosphorylation inhibitor) did not block MAPK activa-
tion by Ang II (Fig. 8B), suggesting that transactivation of
EGF-R may not contribute to Ang II-mediated MAPK
activation in hepatocytes. To investigate possible involve-
ment of the PDGF-R in Ang II-stimulated MAPK activation,
pretreatment of hepatocytes with AG1296 (5–50 AM)
[30,31], a potent and specific inhibitor of PDGF-R autophos-
phorylation, decreased Ang II-stimulated MAPK phosphor-
ylation in a dose-dependent manner (Fig. 8E) [54.5F 5.1%
(n = 3) inhibition of p42 MAPK and 45.8F 6.5% (n = 3)
inhibition of p44 MAPK in the presence of AG1296, 50
AM]. These results suggest that transactivation of PDGF-R
may contribute to Ang II-mediated MAPK activation.
3.8. Role of PKC in Ang II-induced MAPK phosphorylation
To investigate the role of PKC in Ang II-stimulated
MAPK phosphorylation, we treated hepatocytes with PMA
(0.1 AM) for 5 min and observed a significant increase in
MAPK phosphorylation (Fig. 9C). Hepatocytes were pre-
treated for 30 min with PKC inhibitor, Ro 31-8220 (1–5 AM)
or GF 109203X (1–5 AM). These cells were then stimulated
with 100 nM Ang II for 5 min. As shown in Fig. 9A,B,
pretreatment with the PKC inhibitor Ro 31-8220 (2 AM)
reduced Ang II-activated MAPK phosphorylation by
60.1F 4.5% (n = 3) for p42 MAPK and 85.4F 1.6% (n = 3)
for p44 MAPK. In the presence of high concentrations of Ro
31-8220 (5 AM), MAPK phosphorylation was almost com-
pletely abolished. GF 109203X (5 AM), another PKC inhib-
itor, also blocked Ang II-induced MAPK phosphorylation by
44.2F 6.9%(n = 3)forp42MAPKand63.4F 1.7%(n = 3)p44
MAPK. Finally, hepatocytes were pretreated with PMA (1
AM, for 24 h) to downregulate PKC. As shown in Fig. 9C,
downregulation of PKC reduced MAPK phosphorylation by
51.5F 1.7%(n = 3)forp42MAPKand58.9F 5.6%(n = 3)for
p44MAPK in response to Ang II, and 27.2F 3.6% (n = 3) for
p42 MAPK and 54.5F 2.5% (n = 3) for p44 MAPK in
response to PMA. Taken together, these data indicate that
Ang II activates MAPK in a PKC-dependent manner.
3.9. Effects of inhibitors of PtdIns-3-kinase, Src kinase, and
MEK on Ang II-induced MAPK phosphorylation
Phosphatidylinositol-3-kinase (PtdIns-3-Kinase) and Src
kinase have been implicated in MAPK signaling via GPCRs
[32]. To ascertain their role in the Ang II activation of
MAPK in hepatocytes, we examined the effects of selected
kinase inhibitors, such as LY294002 (PtdIns-3-Kinase);
herbimycin and 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyr-
azolo[3,4-d]pyrimidine (PP-1) (Src family tyrosine kinases);
and U-0126 (MEK). The criteria for choosing the concen-
tration of the various inhibitors were based on literature
values and our preliminary results on dose selections.
Hepatocytes were pretreated with LY294002 (10, 50, and
100 AM) or herbimycin (10 AM) or PP-1 (10 AM) or U-0126
(10 AM) for 30 min, then stimulated with Ang II for 5 min.
As shown in Fig. 10A, LY294002 had no effect on basal
MAPK activity but significantly decreased MAPK phos-
phorylation by Ang II. Wortmannin (50 nM), another
PtdIns-3-kinase inhibitor, also blocked Ang II-induced
MAPK phosphorylation (data not shown). These results
suggest a role for PtdIns-3-kinase in Ang II-induced MAPK
phosphorylation in hepatocytes. Herbimycin reduced Ang
II-stimulated MAPK phosphorylation by 36.3F 5.2%
(n = 3) for p42 MAPK and 27.7F 3.1% (n = 3) for p44
MAPK. PP-1 decreased Ang II-activated MAPK phosphor-
ylation by 53.2F 3.9% (n = 3) for p42 MAPK and
45F 6.3% (n = 3) for p44 MAPK (Fig. 10B). The increase
of MAPK phosphorylation by Ang II was completely
blocked by MEK inhibitor, U-0126 (Fig. 10C).
4. Discussion
The two major subtypes of the seven-membrane-span-
ning Ang II receptors (AT1R and AT2R) generate intra-
cellular signals through heterotrimeric G proteins. In
hepatocytes, losartan, an AT1R antagonist, completely
blocked MAPK activation induced by Ang II whereas
AT2R antagonist, PD 123319, had no effect. These data
indicate that Ang II responses are through AT1R in hep-
atocytes. It has been reported that AT1R couples to Gq in
cardiac myocytes [33] and vascular smooth muscle cells
[22] and to both Gq and Gi in liver epithelial cells [25]. Our
data demonstrated that pretreatment with PTX inhibited Ang
II-induced MAPK phosphorylation by 38F 9% and
42F 8% for p44 and p42, respectively. Pretreatment with
GP antagonist-2 had significant inhibition on Ang II-
induced activation of MAPK. These data indicate that
AT1R may couple to Gi in hepatocytes.
Tyrosine phosphorylation of FAK using anti-phosphotyr-
osine Ab and FAK autophosphorylation at Tyr397 in
response to Ang II were detectable. Furthermore, we also
demonstrated that Ang II stimulated an increase in complex
formation between FAK and Src. These results indicate that
there is a cross-talk between GPCRs (e.g. Ang II receptor)
and cytoplasmic tyrosine kinases (e.g. FAK and Src) in
hepatocytes. Inhibition of Src kinases by PP-1 blocked Ang
II-mediated FAK phosphorylation in hepatocytes. However,
BAPTA-AM, an intracellular calcium chelator, had no effect
on FAK phosphorylation by Ang II. Tyr397 has been
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identified as the major site of FAK autophosphorylation and
the binding site for the Src homology 2 (SH2) domains of
Src family kinases [34]. Our results reported here suggest
that Src may function as an upstream regulator of Ang II-
induced FAK tyrosine phosphorylation and that Ang II
stimulates FAK phosphorylation by a calcium-independent
mechanism. The cellular mechanisms by which FAK is
phosphorylated are not clearly defined, but recent studies
implicate a role for the MAPK activation [35]. Once FAK is
phosphorylated, it would provide docking sites for the SH2
domains of the Shc and Grb2 adapter proteins, resulting in
the recruitment of Ras-GTP to the membrane. The activa-
tion of Ras would induce the Raf kinase activity, which
initiates the phosphorylation cascade leading to MAPK
activation. Therefore, activation of FAK and Src may be
implicated in the Ang II-induced MAPK activation in
hepatocytes. We also demonstrated that intracellular calcium
chelator BAPTA-AM and Src kinase inhibitors PP-1 and
herbimycin do not completely inhibit MAPK phosphoryla-
tion induced by Ang II. These partial inhibitions indicate
that at least two signaling pathways lead to MAPK activa-
tion by Ang II, one is calcium-dependent pathway involving
Ca/CaM kinase; the other is calcium-independent pathway,
involving FAK phosphorylation (hence Src/FAK interac-
tion). Again, the Src inhibitor PP-1 inhibits FAK activation
but has much lesser effect on MAPK. This further supports
that Src is the upstream regulator of FAK activation and that
Src activation is one of the mechanisms for activation of
MAPK in hepatocytes.
PKC involvement in the MAPK activation by Ang II
varies in the cell type. In cardiac myocytes, Ang II activates
MAPK through the PKC-dependent pathway [36]. How-
ever, in cardiac fibroblasts [33] and vascular smooth muscle
cells [22], tyrosine kinases and intracellular Ca2+, but not
PKC, play roles in Ang II-induced MAPK activation.
Hence, results vary for the role of PKC in the Ang II-
induced MAPK activation in different cell types. In the
present study, BAPTA-AM, an intracellular Ca2+ chelator,
blocked Ang II-induced MAPK activation, suggesting a role
for intracellular Ca2+. Ro 31-8220 and GF 109203X blocked
Ang II-induced MAPK activation, indicating that Ang II
increases MAPK activity via PKC. Although detailed
mechanisms by which increased Ca2+ results in the activa-
tion of MAPK have not been clearly understood, the
involvement of Ca2+/CaM kinase signaling pathway has
been suggested. We found that Ca/CaM kinase inhibitors,
KN-62 and KN-93, blocked Ang II-induced MAPK phos-
phorylation in hepatocytes, indicating the involvement of
Ca2+/CaM kinase in the MAPK phosphorylation. Taken
together, in hepatocytes, Ang II-induced MAPK activation
is PKC and Ca2+/CaM kinase dependent.
Cross-talk between EGF-R and GPCR influences MAPK
in many cells. For example, in Rat-1 fibroblasts, LPA-,
endothelin-1 (ET-1)-, and thrombin-induced MAPK activa-
tion was blocked by an EGF-R selective tyrosine kinase
inhibitor, AG1478 [37]. These data suggest that EGF-R
tyrosine phosphorylation may be involved in GPCR-
induced MAPK activation. On the contrary, another study
indicated that EGF-R was not phosphorylated by LPA in
Rat-1 fibroblasts [38]. In the present study, we observed
that Ang II did not induce EGF-R tyrosine phosphorylation
and there was no change in the EGF-R protein expression.
These data suggest that EGF-R has no role in MAPK
activation by Ang II in hepatocytes. A more recent study
indicates that Ang II stimulated MAPK activation in
human mesangial cells involves PDGF-R tyrosine phos-
phorylation, but not EGF-R tyrosine phosphorylation [18].
In the present study, AG 1296 inhibited Ang II-stimulated
MAPK phosphorylation, suggesting the involvement of the
PDGF-R in MAPK activation stimulated by Ang II in
hepatocytes.
There is evidence that activation of the MAPK cascade is
mediated, at least in part, by PtdIns-3-kinase depending on
the cell type and stimulus used. In primary hepatocytes,
PtdIns-3-kinase is upstream of MAPK in the insulin signal-
ing pathway [39]. Ang II also induces activation of PtdIns-
3-kinase in cardiomyocytes [40]. Recent evidence indicates
that PKC~ [41], p21-activated kinase (PAK) [42], and Src-
related kinase [43] may be involved in the activation of
MAPK through PtdIns-3-kinase. In the present study, we
demonstrated that inhibition of PtdIns-3-kinase by
LY294002 and wortmannin blocked MAPK activation
stimulated by Ang II, suggesting a role for PtdIns-3-kinase
in MAPK signaling in hepatocytes.
In conclusion, Ang II activation of MAPK is mediated by
a Ca2+/CaM dependent protein kinase and PKC-dependent
pathways and that activation of Src and FAK serve as
intermediary links between Ang II receptor and p42/44
MAPK activation. Furthermore, PDGF-R phosphorylation/
transactivation, but not EGF-R phosphorylation/transactiva-
tion, is involved in this mechanism. These studies highlight
the dependency of Ang II-activated p42/44 MAPK on
multiple signaling networks and provide the basis for
mechanistic elucidation of these cross-talks and for the
determination of their hierarchy in hepatocytes.
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